Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

72.09
-5.8100-7.46%
Post-market: 73.000.9100+1.26%19:55 EDT
Volume:4.36M
Turnover:317.52M
Market Cap:10.02B
PE:-10.04
High:74.42
Open:73.88
Low:71.66
Close:77.90
52wk High:88.31
52wk Low:35.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:3.44
T/O Rate:3.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-57.77
PE(LYR):-11.02

Loading ...

Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale

TIPRANKS
·
Aug 19

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of 3,500 Common Shares for $265,370

Reuters
·
Aug 19

Cytokinetics Grants New-Hire Equity Awards, Stock Options Priced at $74.13 Per Share

Reuters
·
Aug 19

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 19

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 19

Cytokinetics price target raised to $103 from $97 at JPMorgan

TIPRANKS
·
Aug 17

Barclays Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Aug 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 14

Cytokinetics is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 13

Cytokinetics Files Patent Suit to Protect MYQORZO Franchise

TIPRANKS
·
Aug 13

Cytokinetics - Files Complaint Against Bristol-Myers Squibb and Myokardia - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Demands Trial by Jury on All Triable Issues - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Seeks Injunction Against Litigation or Infringement Claims on Myqorzo(Aficamten) - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics Sues Bristol Myers, MyoKardia Seeking Ruling on Myqorzo Patent Dispute

Reuters
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Cytokinetics, Incorporated : JP Morgan Raises Target Price to $103 from $97

THOMSON REUTERS
·
Aug 13

Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Aug 13

Cytokinetics CEO Robert I. Blum Sells 7,500 Common Shares for $575,700

Reuters
·
Aug 11

Cytokinetics is Maintained at Buy by Truist Securities

Dow Jones
·
Aug 11

Cytokinetics price target raised to $112 from $106 at Truist

TIPRANKS
·
Aug 10